[go: up one dir, main page]

WO2017120568A8 - Apoe mimetic peptide compositions - Google Patents

Apoe mimetic peptide compositions Download PDF

Info

Publication number
WO2017120568A8
WO2017120568A8 PCT/US2017/012678 US2017012678W WO2017120568A8 WO 2017120568 A8 WO2017120568 A8 WO 2017120568A8 US 2017012678 W US2017012678 W US 2017012678W WO 2017120568 A8 WO2017120568 A8 WO 2017120568A8
Authority
WO
WIPO (PCT)
Prior art keywords
mimetic peptide
peptide compositions
apoe mimetic
apoe
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2017/012678
Other languages
French (fr)
Other versions
WO2017120568A1 (en
Inventor
Dennis I Goldberg
Phillip M FRIDEN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LipimetiX Development LLC
Original Assignee
LipimetiX Development LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LipimetiX Development LLC filed Critical LipimetiX Development LLC
Publication of WO2017120568A1 publication Critical patent/WO2017120568A1/en
Publication of WO2017120568A8 publication Critical patent/WO2017120568A8/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Disclosed are aqueous compositions comprising a mixture of synthetic apolipoprotein E (ApoE)-mimicking peptides and a polyethylene sorbitan ester, and their use in reducing plasma cholesterol.
PCT/US2017/012678 2016-01-08 2017-01-09 Apoe mimetic peptide compositions Ceased WO2017120568A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662276295P 2016-01-08 2016-01-08
US62/276,295 2016-01-08
US201662288748P 2016-01-29 2016-01-29
US62/288,748 2016-01-29

Publications (2)

Publication Number Publication Date
WO2017120568A1 WO2017120568A1 (en) 2017-07-13
WO2017120568A8 true WO2017120568A8 (en) 2017-08-10

Family

ID=57960820

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2017/012678 Ceased WO2017120568A1 (en) 2016-01-08 2017-01-09 Apoe mimetic peptide compositions

Country Status (1)

Country Link
WO (1) WO2017120568A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018190896A1 (en) * 2017-04-13 2018-10-18 Lipimetix Development, Inc. Apoe mimetic peptide compositions
TW202010752A (en) * 2018-04-11 2020-03-16 美商立畢密蒂斯發展公司 APOE mimetic peptide compositions

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6506880B2 (en) 1998-03-17 2003-01-14 The Uab Research Foundation Synthetic peptides that enhance atherogenic lipoprotein uptake and lower plasma cholesterol
CA2697957A1 (en) 2007-08-28 2009-03-12 Uab Research Foundation Synthetic apolipoprotein e mimicking polypeptides and methods of use
JP6570511B2 (en) * 2013-03-14 2019-09-04 ユーエイビー リサーチ ファンデーション Apolipoprotein mimics and uses thereof
JP7081923B2 (en) * 2014-07-31 2022-06-07 ユーエイビー リサーチ ファンデーション Higher effectiveness for removing apoE mimetic peptides and plasma cholesterol

Also Published As

Publication number Publication date
WO2017120568A1 (en) 2017-07-13

Similar Documents

Publication Publication Date Title
WO2015063465A3 (en) Novel polypeptides
IL240357A (en) Apolipoprotein a-i mimic peptides, compositions comprising the same and uses thereof
WO2014096440A3 (en) Albumin composition for preventing and/or reducing formation of peptide fibrils
WO2012158964A3 (en) Improved peptide pharmaceuticals for osteoporosis
WO2015179635A3 (en) Ras inhibitory peptides and uses thereof
WO2015063747A3 (en) Peptide inhibitors of tead/yap-taz interaction
EP3130345A4 (en) Peptide having fibrosis inhibitory activity and composition containing same
EP3189069A4 (en) Apoe mimetic peptides and higher potency to clear plasma cholesterol
BR112013030824A8 (en) GRAM-POSITIVE BACTERIA, RECOMBINANT NECLEIC ACID, PHARMACEUTICAL COMPOSITION AND VECTOR
WO2015185758A3 (en) Preparation comprising factor viii and von willebrand factor peptides
HK1245302A1 (en) Carrier molecule compositions and related methods
EP3642219A4 (en) Peptide compositions and related methods
EP4168028A4 (en) Sars-cov-2 immunodominant peptides and uses thereof
EP3505530A4 (en) Scorpion venom heat-resistant synthesized peptide and uses thereof
WO2017120568A8 (en) Apoe mimetic peptide compositions
WO2012097220A3 (en) Novel vesicles and nanostructures from recombinant proteins
EP3399990A4 (en) Therapeutic compositions including peptides and uses thereof
AU2020234373A1 (en) Novel peptide and use thereof
EP3996737A4 (en) Peptides and uses thereof
WO2017190032A3 (en) Therapeutic sall4 peptide
AU2018275270A1 (en) Peptide PAC1 antagonists
HK40083610A (en) Composition comprising thrombin derived peptides and use thereof
HK40063851A (en) Novel peptides and uses thereof
AU2019903904A0 (en) Liposomes and uses thereof
WO2015114633A8 (en) Actin binding peptides and compositions comprising same for inhibiting angiogenesis and treating medical conditions associated with same

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17702976

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 17702976

Country of ref document: EP

Kind code of ref document: A1